A phase IIb trial in systemic lupus erythematosus (SLE) showed that low-dose interleukin-2 therapy can restore regulatory T cells in a dose-dependent way, according to results published in Nature Communications. The study supports the rationale that targeted cytokine modulation can rebalance immune regulation without broad immunosuppression. The trial adds to IL-2’s role as a biologically guided autoimmune approach, aiming to increase Treg function while minimizing the risk of expanding inflammatory T cell populations. For biotech teams, the readout strengthens the case for Treg-centric combination strategies and for refined dosing regimens tied to immunophenotyping. The data could shape late-stage trial design around biomarkers and patient selection using Treg response as an early efficacy signal.